<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02551679</url>
  </required_header>
  <id_info>
    <org_study_id>HS 12-01.</org_study_id>
    <nct_id>NCT02551679</nct_id>
  </id_info>
  <brief_title>ACP-01 in Patients With Critical Limb Ischemia</brief_title>
  <official_title>A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Derived Autologous Angiogenic Cell Precursor Therapy in Patients With Critical Limb Ischemia (ACP-CLI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hemostemix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hemostemix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the efficacy and safety of intramuscular
      injection of ACP-01, comprised of blood-derived autologous ACPs, in subjects with critical
      limb ischemia who are receiving standard of care therapy and have no endovascular or surgical
      revascularization options.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, randomized, double-blind, placebo controlled study will assess the efficacy
      and safety of autologous ACPs administered intramuscularly into the lower extremity of
      subjects with CLI who lack surgical or endovascular revascularization options.

      A total of approximately 95 subjects will be randomized to treatment with ACP-01 or placebo
      using a 2:1 randomization scheme, respectively, stratified by site.

      The study will continue until all subjects treated experience the study event (either de novo
      gangrene, doubling of wound size, major amputation, or death) or are event-free for at least
      26 weeks. Subjects treated will be followed for no longer than 52 weeks.

      One futility analysis for potentially stopping study enrollment will be performed.

      Subjects treated at each investigative site will provide written informed consent prior to
      the conduct of any study-related procedures. Thereafter, they will be screened and those
      meeting the inclusion/exclusion criteria will be enrolled into the trial and undergo all the
      study procedures including intramuscular injection of the investigational medicinal product
      (IMP = ACP-01 or placebo). The IMP will be administered in addition to any conventional
      treatment the subject is receiving.

      The control group will receive placebo injections into the lower extremity to ensure blinding
      of the assessors and the subjects.

      The placebo will consist of the same medium used in the ACP product suspension.

      The study consists of four periods: Screening period, Treatment period, Acute safety
      follow-up and Long term follow-up periods. The total duration of study participation,
      including follow-up, is at least 26 weeks. Subjects will be followed for up to 52 weeks and
      at least until the last subject has completed his/her 26 week visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Size, Amputation or Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Time to doubling of wound size, major amputation or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Level</measure>
    <time_frame>1 year</time_frame>
    <description>Change in pain score according to the Visual Analog Scale for Pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ulcer Size</measure>
    <time_frame>1 year</time_frame>
    <description>Change in ulcer size</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in the dose and quantity of analgesic drugs used by the subject</measure>
    <time_frame>1 - 52 wks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Reduction in total hospitalization time of subjects treated with ACP-01 compared to subjects treated with placebo</measure>
    <time_frame>1 - 52 wks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in Quality of Life</measure>
    <time_frame>1 - 52 wks</time_frame>
    <description>Change in quality of life according to the Vascular Quality of Life Questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in Ankle Pressure</measure>
    <time_frame>1 - 52 wks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in Toe Pressure</measure>
    <time_frame>1 - 52 wks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>ACP-01</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection into lower extremity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection into lower extremity</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACP-01</intervention_name>
    <description>Injection into lower extremity</description>
    <arm_group_label>ACP-01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injection into lower extremity</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is diagnosed with critical limb ischemia.

          -  Subject has hemodynamic indicators of severe peripheral arterial occlusive disease.

          -  Subject is not a candidate for standard revascularization treatment options for
             peripheral arterial disease.

          -  Subject must be on standard of care medical therapy for peripheral vascular disease.

          -  Male or female age 18 and above.

          -  Non-pregnant, non-lactating female.

          -  Subject is able to understand and provide voluntary signed informed consent.

        Exclusion Criteria:

          -  Uncorrected aorto-iliac occlusive disease.

          -  Subjects who, in the opinion of the investigator, have a vascular disease prognosis
             that indicates they would require a major amputation in a time frame shortly after
             administration of the IMP (investigational drug or placebo).

          -  Advanced Critical Limb Ischemia (CLI) presenting as severe ischemic or dry gangrene.

          -  Lower extremity non-treated active infection.

          -  Hypercoagulable state.

          -  Subject received a blood transfusion during the previous 4 weeks (to exclude the
             potential of non-autologous ACPs in the harvested blood).

          -  Inability to communicate that may interfere with clinical evaluation.

          -  Recent major non-vascular operation.

          -  Myocardial infarction or uncontrolled myocardial ischemia or persistent severe heart
             failure.

          -  Severe aortic stenosis.

          -  Renal failure.

          -  Hepatic failure.

          -  Anemia.

          -  Major stroke.

          -  Diagnosis of malignancy.

          -  Concurrent chronic or acute infectious disease and uncontrolled infectious symptoms.

          -  Severe concurrent disease (other than Peripheral Vascular Disease (PAD)).

          -  Bleeding diathesis.

          -  Participation at the same time in another investigational product or device study.

          -  Chronic cytotoxic drug treatment.

          -  Life expectancy of less than 6 months.

          -  Subject unlikely to be available for follow-up.

          -  Acute worsening of CLI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alan Jacobs, MSEE MD PhD</last_name>
    <email>regulatory@aspire2cure.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>OrthoArizona</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Wallace</last_name>
      <phone>800-774-1534</phone>
      <email>r.wallace@prgresearch.com</email>
    </contact>
    <investigator>
      <last_name>Lewis Freed, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis CTSC Clinical Research Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura B Jones</last_name>
      <phone>916-734-4156</phone>
      <email>lbjjones@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Mell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Regional VA Medical Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Corbet</last_name>
      <email>michele.corbet@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Ehrin Armstrong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Harvey, MSHS</last_name>
      <phone>352-273-5482</phone>
      <email>lmharvey@ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nancy Hanson</last_name>
      <phone>(352)273-5479</phone>
      <email>nancy.hanson@surgery.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kristina Giles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinovation Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandro Viloria</last_name>
      <phone>786-468-7425</phone>
      <email>alejandroviloria@clinovationresearch.com</email>
    </contact>
    <investigator>
      <last_name>Francisco Perez-Clavijo, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Guala, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Central Florida</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennel Smith, BS</last_name>
      <phone>863-853-5400</phone>
      <email>jsmith@clinicalresearchcf.com</email>
    </contact>
    <contact_backup>
      <last_name>Marty Fisher, BA</last_name>
      <phone>863-293-1191</phone>
      <phone_ext>3674</phone_ext>
      <email>mfisher@clinicalresearchcf.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cary J Lambert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jade Becker</last_name>
      <email>becker.jade@mhsil.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Trachtenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Evans</last_name>
      <phone>708-216-1166</phone>
      <email>mevans11@luc.edu</email>
    </contact>
    <investigator>
      <last_name>Bernadette Aulivola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shauneen Valliere</last_name>
      <phone>508-856-1767</phone>
      <email>shauneen.valliere@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Andres Schanzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tori Barker</last_name>
      <phone>603-650-6379</phone>
      <email>dorothy.h.barker@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Philip Goodney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers University New Jersey Medical School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Bott</last_name>
      <phone>973-972-3250</phone>
      <email>kb753@njms.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Joe T Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moses H. Cone Memorial Hospital</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Hedrick</last_name>
      <phone>336-832-3796</phone>
      <email>tammy.hedrick@conehealth.com</email>
    </contact>
    <investigator>
      <last_name>Vance W Brabham IV, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rob Paris</last_name>
      <phone>336-716-3296</phone>
      <email>rparis@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Justin Hurie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Stout, RN</last_name>
      <phone>405-271-9060</phone>
      <phone_ext>44761</phone_ext>
      <email>michael-h-stout@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Beau Hawkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Hosptial</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia McNelis</last_name>
      <phone>215-707-5187</phone>
      <email>patricia.mcnelis@tuhs.temple.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Schaffner</last_name>
      <phone>843-793-7558</phone>
      <email>schaffne@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas E Brothers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist DeBakey Heart &amp; Vascular Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bevin Lopez, MS</last_name>
      <phone>713-441-6537</phone>
      <email>balopez@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Eric Peden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc. (CTT)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Ramos, BS</last_name>
      <phone>210-949-0122</phone>
      <phone_ext>177</phone_ext>
      <email>cramos@cttexas.com</email>
    </contact>
    <investigator>
      <last_name>Boulos Toursarkissian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1K3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lissette Araya, BSN</last_name>
      <phone>604 875-5077</phone>
      <email>lissette.araya@vch.ca</email>
    </contact>
    <investigator>
      <last_name>York Hsiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Novick</last_name>
      <phone>(519) 685-8500</phone>
      <phone_ext>75926</phone_ext>
      <email>teresa.novick@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Adam Power, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hemostemix.com</url>
    <description>Hemostemix Inc. website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 14, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem cells</keyword>
  <keyword>Autologous</keyword>
  <keyword>Vascular disease</keyword>
  <keyword>Peripheral arterial disease</keyword>
  <keyword>Regenerative medicine</keyword>
  <keyword>Amputation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

